Live Breaking News & Updates on Edoxaban Clinical Research Programme

Stay updated with breaking news from Edoxaban clinical research programme. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Daiichi Sankyo: New data further strengthens important role of LIXIANA (edoxaban) in managing complex patient populations with atrial fibrillation (AF)

Data from the ETNA-AF-Europe Registry provide insights on edoxaban in routine clinical practice in patient subpopulations including those who are frail, with heart failure or insulin-dependent diabetes1 ....

Wolfgang Schiessl , Stefan Seyfried , Daiichi Sankyo , Daiichi Sankyo Europe , Daiichi Sankyo Europe Gmb , University Of Pisa , European Society Of Cardiology Congress , Pisa University Hospital , Sustainable Development Of Society , Innovative Global Healthcare Company , European Society Of Cardiology , European Heart Rhythm Association Practical , University Cardiology Division , Edoxaban Clinical Research Programme , Europe Registry , European Society , Sankyo Europe , Cardiology Congress , Raffaele De Caterina , Pisa University , Vice President , Medical Affairs , Specialty Medicines , Global Healthcare Company Contributing , Sustainable Development , Exodaban Treatment ,

New data further strengthens important role of LIXIANA® (edoxaban) in managing complex patient populations with atrial fibrillation (AF)

New data further strengthens important role of LIXIANA® (edoxaban) in managing complex patient populations with atrial fibrillation (AF)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Wolfgang Schiessl , Stefan Seyfried , Daiichi Sankyo , Daiichi Sankyo Europe , Daiichi Sankyo Europe Gmb , University Of Pisa , European Society Of Cardiology Congress , Pisa University Hospital , Sustainable Development Of Society , Innovative Global Healthcare Company , European Society Of Cardiology , European Heart Rhythm Association Practical , University Cardiology Division , Edoxaban Clinical Research Programme , Europe Registry , European Society , Sankyo Europe , Cardiology Congress , Non Vitamink Antagonist Oral Anticoagulants , Atrial Fibrillation , Practical Guide , Raffaele De Caterina , Pisa University , Vice President , Medical Affairs , Specialty Medicines ,

Daiichi Sankyo: New data support the use of LIXIANA (edoxaban) in complex patient populations with atrial fibrillation (AF)

Data from the ETNA-AF-Europe Registry provide insights on edoxaban in clinical routine practice in subpopulations including frail patients and those with worsening renal function. ENVISAGE-TAVI ....

George Dangas , Wolfgang Schiessl , Hein Heidbuchel , Nicolas Van Mieghem , Daiichi Sankyo , Daiichi Sankyo Europe , Daiichi Sankyo Europe Gmb , European Heart Rhythm Association , Michaela Wiener Cardiovascular Institute , Cardiology At Antwerp University , International Society On Thrombosis , Erasmus University Medical Center , Portfolio Communications , Sustainable Development Of Society , European Association For Cardio , Icahn School Of Medicine At Mount Sinai , Innovative Global Healthcare Company , European Society Of Cardiology , European Heart Rhythm Association Practical , Edoxaban Clinical Research Programme , Europe Registry , Sankyo Europe , European Society , Hot Line , New England Journal , Atrial Fibrillation ,

Daiichi Sankyo Europe: New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA (edoxaban) in people with atrial fibrillation

(0)
Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48
ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study investigating a single non-vitamin K antagonist oral anticoagulant (NOAC) to date
Data presented at the annual scientific meeting of the European Heart Rhythm Association
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced the presentation of new routine clinical practice outcomes data confirming, in line with the randomised clinical trial data, the consistent effectiveness and safety profile of LIXIANA ....

Noord Holland , The Netherlands , Wolfgang Schiessl , Daiichi Sankyo , Garth Virgin , Daiichi Sankyo Europe , Daiichi Sankyo Europe Gmb , European Heart Rhythm Association , Atrial Fibrillation At University Of Amsterdam , Affairs Specialty Medicines At Daiichi Sankyo Europe , Amsterdam University Medical Centers , Daiichi Sankyo Group , Portfolio Communications , Edoxaban Clinical Research Programme , Sankyo Europe , Cardiac Electrophysiology , Atrial Fibrillation , Edoxaban Treatment , Sankyo Group , Pharma Innovator , Competitive Advantage , Sankyo Europe Gmbh , Cardiovascular Europe , நூற்த் ஹாலண்ட் , தி நெதர்லாந்து , தய்ச்சி சாங்கியோ ,

New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with atrial fibrillation

New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with atrial fibrillation
04/26/2021 | 03:01am EDT
Send by mail :
Message :
Required fields
Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48
ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study investigating a single non-vitamin K antagonist oral anticoagulant (NOAC) to date
Data presented at the annual scientific meeting of the European Heart Rhythm Association
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced the presentation of new routine clinical practice outcomes data confirming, in line with the randomised clinical trial data, the consistent effectiveness and safety pr ....

Noord Holland , The Netherlands , Daiichi Sankyo , Garth Virgin , Daiichi Sankyo Europe , European Heart Rhythm Association , Atrial Fibrillation At University Of Amsterdam , Affairs Specialty Medicines At Daiichi Sankyo Europe , Amsterdam University Medical Centers , Daiichi Sankyo Group , Edoxaban Clinical Research Programme , Cardiac Electrophysiology , Atrial Fibrillation , Edoxaban Treatment , Sankyo Group , Pharma Innovator , Competitive Advantage , நூற்த் ஹாலண்ட் , தி நெதர்லாந்து , தய்ச்சி சாங்கியோ , தய்ச்சி சாங்கியோ யூரோப் , ஐரோப்பிய இதயம் தாளம் சங்கம் , ஆம்ஸ்டர்டாம் பல்கலைக்கழகம் மருத்துவ மையங்கள் , தய்ச்சி சாங்கியோ குழு , இதய மின் இயற்பியல் , ஏட்ரியல் குறு நடுக்கம் ,